In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV
about
GS-8374, a Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits Protease Mutants with Amino Acid InsertionsCurrent and Novel Inhibitors of HIV ProteaseFluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivoEnhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDSBlockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cellsThe naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviralIn vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.Ion specific effects of alkali cations on the catalytic activity of HIV-1 protease.Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4+ T Cells Through Cyclic Adenosine Monophosphate-Dependent Mechanisms in Humanized Mice In Vivo.
P2860
Q27681100-A954B65C-1CE2-4310-8A32-1DEEA899BBE5Q35259915-FC5C8ED1-3AF5-49DE-94DE-8CFE5CD051A0Q35935885-EC1887B5-8CE7-4F4D-8562-99151E57D79FQ37256641-F498A4FB-E3C3-4CA6-9A41-A79C1E4955A2Q37980084-478A9BDF-2E70-435C-8227-02929EC1D1AFQ38708006-7E474F6D-233D-4A1D-BCF7-74238DEBEF08Q39104422-C979B17D-E20B-4259-B189-275BA69B6898Q39862376-F33FC424-0604-49F0-8493-65211EE1D897Q40030648-3ACE6169-5A15-45DD-B962-99872B3DF996Q41875646-F2D0D928-517F-4477-85F9-47B6973738ECQ42288628-484A8237-15E0-48E5-A941-FD33E9D51A49Q47608472-182EEE17-3438-488A-8B67-E8D8DD20F500
P2860
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@ast
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@en
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@nl
type
label
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@ast
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@en
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@nl
prefLabel
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@ast
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@en
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@nl
P2093
P2860
P921
P356
P1476
In vitro antiviral activity of ...... otease inhibitor-resistant HIV
@en
P2093
Andrew Spaltenstein
Eric Furfine
Istvan Kaldor
John Miller
Lawrence Boone
Marty St Clair
Mary Hanlon
Michael Hale
Philip Griffin
P2860
P304
P356
10.1128/AAC.00401-07
P407
P577
2007-07-09T00:00:00Z